Is ImageneBio, Inc. (IMA) overvalued? · rev $9.2M
ImageneBio, Inc. (IMA) is a biotechnology company listed on NASDAQ.
This page asks whether ImageneBio, Inc. (IMA) looks expensive on cached numbers — not a short thesis.
Latest reported IMA revenue for 2023-12-31 was $9.2M. Net income was -$68.2M. Revenue was down 41.3% from 2022-12-31 to 2023-12-31. IMA currently screens at market cap $64.7M.
IMA currently screens at market cap $64.7M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next IMA 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the IMA stock page for the full model, not this heading.
Not investment advice.